Cargando…

Recombinant vesicular stomatitis vaccine against Nipah virus has a favorable safety profile: Model for assessment of live vaccines with neurotropic potential

Nipah virus (NiV) disease is a bat-borne zoonosis responsible for outbreaks with high lethality and is a priority for vaccine development. With funding from the Coalition of Epidemic Preparedness Innovations (CEPI), we are developing a chimeric vaccine (PHV02) composed of recombinant vesicular stoma...

Descripción completa

Detalles Bibliográficos
Autores principales: Monath, Thomas P., Nichols, Richard, Tussey, Lynda, Scappaticci, Kelly, Pullano, Thaddeus G., Whiteman, Mary D., Vasilakis, Nikos, Rossi, Shannan L., Campos, Rafael Kroon, Azar, Sasha R., Spratt, Heidi M., Seaton, Brent L., Archambault, W. Tad, Costecalde, Yanina V., Moore, Evan H., Hawks, Roger J., Fusco, Joan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9269911/
https://www.ncbi.nlm.nih.gov/pubmed/35759511
http://dx.doi.org/10.1371/journal.ppat.1010658
_version_ 1784744336874799104
author Monath, Thomas P.
Nichols, Richard
Tussey, Lynda
Scappaticci, Kelly
Pullano, Thaddeus G.
Whiteman, Mary D.
Vasilakis, Nikos
Rossi, Shannan L.
Campos, Rafael Kroon
Azar, Sasha R.
Spratt, Heidi M.
Seaton, Brent L.
Archambault, W. Tad
Costecalde, Yanina V.
Moore, Evan H.
Hawks, Roger J.
Fusco, Joan
author_facet Monath, Thomas P.
Nichols, Richard
Tussey, Lynda
Scappaticci, Kelly
Pullano, Thaddeus G.
Whiteman, Mary D.
Vasilakis, Nikos
Rossi, Shannan L.
Campos, Rafael Kroon
Azar, Sasha R.
Spratt, Heidi M.
Seaton, Brent L.
Archambault, W. Tad
Costecalde, Yanina V.
Moore, Evan H.
Hawks, Roger J.
Fusco, Joan
author_sort Monath, Thomas P.
collection PubMed
description Nipah virus (NiV) disease is a bat-borne zoonosis responsible for outbreaks with high lethality and is a priority for vaccine development. With funding from the Coalition of Epidemic Preparedness Innovations (CEPI), we are developing a chimeric vaccine (PHV02) composed of recombinant vesicular stomatitis virus (VSV) expressing the envelope glycoproteins of both Ebola virus (EBOV) and NiV. The EBOV glycoprotein (GP) mediates fusion and viral entry and the NiV attachment glycoprotein (G) is a ligand for cell receptors, and stimulates neutralizing antibody, the putative mediator of protection against NiV. PHV02 is identical in construction to the registered Ebola vaccine (Ervebo) with the addition of the NiV G gene. NiV ephrin B2 and B3 receptors are expressed on neural cells and the wild-type NiV is neurotropic and causes encephalitis in affected patients. It was therefore important to assess whether the NiV G alters tropism of the rVSV vector and serves as a virulence factor. PHV02 was fully attenuated in adult hamsters inoculated by the intramuscular (IM) route, whereas parental wild-type VSV was 100% lethal. Two rodent models (mice, hamsters) were infected by the intracerebral (IC) route with graded doses of PHV02. Comparator active controls in various experiments included rVSV-EBOV (representative of Ebola vaccine) and yellow fever (YF) 17DD commercial vaccine. These studies showed PHV02 to be more neurovirulent than both rVSV-EBOV and YF 17DD in infant animals. PHV02 was lethal for adult hamsters inoculated IC but not for adult mice. In contrast YF 17DD retained virulence for adult mice inoculated IC but was not virulent for adult hamsters. Because of the inconsistency of neurovirulence patterns in the rodent models, a monkey neurovirulence test (MNVT) was performed, using YF 17DD as the active comparator because it has a well-established profile of quantifiable microscopic changes in brain centers and a known reporting rate of neurotropic adverse events in humans. In the MNVT PHV02 was significantly less neurovirulent than the YF 17DD vaccine reference control, indicating that the vaccine will have an acceptable safety profile for humans. The findings are important because they illustrate the complexities of phenotypic assessment of novel viral vectors with tissue tropisms determined by transgenic proteins, and because it is unprecedented to use a heterologous comparator virus (YF vaccine) in a regulatory-enabling study. This approach may have value in future studies of other novel viral vectors.
format Online
Article
Text
id pubmed-9269911
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-92699112022-07-09 Recombinant vesicular stomatitis vaccine against Nipah virus has a favorable safety profile: Model for assessment of live vaccines with neurotropic potential Monath, Thomas P. Nichols, Richard Tussey, Lynda Scappaticci, Kelly Pullano, Thaddeus G. Whiteman, Mary D. Vasilakis, Nikos Rossi, Shannan L. Campos, Rafael Kroon Azar, Sasha R. Spratt, Heidi M. Seaton, Brent L. Archambault, W. Tad Costecalde, Yanina V. Moore, Evan H. Hawks, Roger J. Fusco, Joan PLoS Pathog Research Article Nipah virus (NiV) disease is a bat-borne zoonosis responsible for outbreaks with high lethality and is a priority for vaccine development. With funding from the Coalition of Epidemic Preparedness Innovations (CEPI), we are developing a chimeric vaccine (PHV02) composed of recombinant vesicular stomatitis virus (VSV) expressing the envelope glycoproteins of both Ebola virus (EBOV) and NiV. The EBOV glycoprotein (GP) mediates fusion and viral entry and the NiV attachment glycoprotein (G) is a ligand for cell receptors, and stimulates neutralizing antibody, the putative mediator of protection against NiV. PHV02 is identical in construction to the registered Ebola vaccine (Ervebo) with the addition of the NiV G gene. NiV ephrin B2 and B3 receptors are expressed on neural cells and the wild-type NiV is neurotropic and causes encephalitis in affected patients. It was therefore important to assess whether the NiV G alters tropism of the rVSV vector and serves as a virulence factor. PHV02 was fully attenuated in adult hamsters inoculated by the intramuscular (IM) route, whereas parental wild-type VSV was 100% lethal. Two rodent models (mice, hamsters) were infected by the intracerebral (IC) route with graded doses of PHV02. Comparator active controls in various experiments included rVSV-EBOV (representative of Ebola vaccine) and yellow fever (YF) 17DD commercial vaccine. These studies showed PHV02 to be more neurovirulent than both rVSV-EBOV and YF 17DD in infant animals. PHV02 was lethal for adult hamsters inoculated IC but not for adult mice. In contrast YF 17DD retained virulence for adult mice inoculated IC but was not virulent for adult hamsters. Because of the inconsistency of neurovirulence patterns in the rodent models, a monkey neurovirulence test (MNVT) was performed, using YF 17DD as the active comparator because it has a well-established profile of quantifiable microscopic changes in brain centers and a known reporting rate of neurotropic adverse events in humans. In the MNVT PHV02 was significantly less neurovirulent than the YF 17DD vaccine reference control, indicating that the vaccine will have an acceptable safety profile for humans. The findings are important because they illustrate the complexities of phenotypic assessment of novel viral vectors with tissue tropisms determined by transgenic proteins, and because it is unprecedented to use a heterologous comparator virus (YF vaccine) in a regulatory-enabling study. This approach may have value in future studies of other novel viral vectors. Public Library of Science 2022-06-27 /pmc/articles/PMC9269911/ /pubmed/35759511 http://dx.doi.org/10.1371/journal.ppat.1010658 Text en © 2022 Monath et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Monath, Thomas P.
Nichols, Richard
Tussey, Lynda
Scappaticci, Kelly
Pullano, Thaddeus G.
Whiteman, Mary D.
Vasilakis, Nikos
Rossi, Shannan L.
Campos, Rafael Kroon
Azar, Sasha R.
Spratt, Heidi M.
Seaton, Brent L.
Archambault, W. Tad
Costecalde, Yanina V.
Moore, Evan H.
Hawks, Roger J.
Fusco, Joan
Recombinant vesicular stomatitis vaccine against Nipah virus has a favorable safety profile: Model for assessment of live vaccines with neurotropic potential
title Recombinant vesicular stomatitis vaccine against Nipah virus has a favorable safety profile: Model for assessment of live vaccines with neurotropic potential
title_full Recombinant vesicular stomatitis vaccine against Nipah virus has a favorable safety profile: Model for assessment of live vaccines with neurotropic potential
title_fullStr Recombinant vesicular stomatitis vaccine against Nipah virus has a favorable safety profile: Model for assessment of live vaccines with neurotropic potential
title_full_unstemmed Recombinant vesicular stomatitis vaccine against Nipah virus has a favorable safety profile: Model for assessment of live vaccines with neurotropic potential
title_short Recombinant vesicular stomatitis vaccine against Nipah virus has a favorable safety profile: Model for assessment of live vaccines with neurotropic potential
title_sort recombinant vesicular stomatitis vaccine against nipah virus has a favorable safety profile: model for assessment of live vaccines with neurotropic potential
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9269911/
https://www.ncbi.nlm.nih.gov/pubmed/35759511
http://dx.doi.org/10.1371/journal.ppat.1010658
work_keys_str_mv AT monaththomasp recombinantvesicularstomatitisvaccineagainstnipahvirushasafavorablesafetyprofilemodelforassessmentoflivevaccineswithneurotropicpotential
AT nicholsrichard recombinantvesicularstomatitisvaccineagainstnipahvirushasafavorablesafetyprofilemodelforassessmentoflivevaccineswithneurotropicpotential
AT tusseylynda recombinantvesicularstomatitisvaccineagainstnipahvirushasafavorablesafetyprofilemodelforassessmentoflivevaccineswithneurotropicpotential
AT scappaticcikelly recombinantvesicularstomatitisvaccineagainstnipahvirushasafavorablesafetyprofilemodelforassessmentoflivevaccineswithneurotropicpotential
AT pullanothaddeusg recombinantvesicularstomatitisvaccineagainstnipahvirushasafavorablesafetyprofilemodelforassessmentoflivevaccineswithneurotropicpotential
AT whitemanmaryd recombinantvesicularstomatitisvaccineagainstnipahvirushasafavorablesafetyprofilemodelforassessmentoflivevaccineswithneurotropicpotential
AT vasilakisnikos recombinantvesicularstomatitisvaccineagainstnipahvirushasafavorablesafetyprofilemodelforassessmentoflivevaccineswithneurotropicpotential
AT rossishannanl recombinantvesicularstomatitisvaccineagainstnipahvirushasafavorablesafetyprofilemodelforassessmentoflivevaccineswithneurotropicpotential
AT camposrafaelkroon recombinantvesicularstomatitisvaccineagainstnipahvirushasafavorablesafetyprofilemodelforassessmentoflivevaccineswithneurotropicpotential
AT azarsashar recombinantvesicularstomatitisvaccineagainstnipahvirushasafavorablesafetyprofilemodelforassessmentoflivevaccineswithneurotropicpotential
AT sprattheidim recombinantvesicularstomatitisvaccineagainstnipahvirushasafavorablesafetyprofilemodelforassessmentoflivevaccineswithneurotropicpotential
AT seatonbrentl recombinantvesicularstomatitisvaccineagainstnipahvirushasafavorablesafetyprofilemodelforassessmentoflivevaccineswithneurotropicpotential
AT archambaultwtad recombinantvesicularstomatitisvaccineagainstnipahvirushasafavorablesafetyprofilemodelforassessmentoflivevaccineswithneurotropicpotential
AT costecaldeyaninav recombinantvesicularstomatitisvaccineagainstnipahvirushasafavorablesafetyprofilemodelforassessmentoflivevaccineswithneurotropicpotential
AT mooreevanh recombinantvesicularstomatitisvaccineagainstnipahvirushasafavorablesafetyprofilemodelforassessmentoflivevaccineswithneurotropicpotential
AT hawksrogerj recombinantvesicularstomatitisvaccineagainstnipahvirushasafavorablesafetyprofilemodelforassessmentoflivevaccineswithneurotropicpotential
AT fuscojoan recombinantvesicularstomatitisvaccineagainstnipahvirushasafavorablesafetyprofilemodelforassessmentoflivevaccineswithneurotropicpotential